Caribou Biosciences, Inc.
NASDAQ:CRBUBiotechnology
-$0.05 today
- Market cap
- $52.47M
- Beta
- 2.33
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$1.39
Volume 1.01M
Average 1.83M
Returns on capital
Caribou Biosciences, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-121.2%
avg -60.8%
ROIC
-89.8%
avg -59.2%
ROA
-84.5%
avg -47.2%
Analysis
ROA is currently the strongest return metric at -84.5% versus its period average of -47.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Rachel E. Haurwitz | Co-Founder, Chief Executive Officer, President & Director | USD 993.61K | 40 | 447.15K | 0.45% |
Timothy Kelly | Chief Technology Officer | USD 730.05K | 56 | — | — |
Barbara G. McClung | Chief Legal Officer & Corporate Secretary | USD 686.72K | 71 | 481.56K | 0.49% |
Tina Albertson | Chief Medical Officer | USD 677.08K | 52 | — | — |
Sriram Ryali | Chief Financial Officer | USD 663.51K | 44 | 72.36K | 0.07% |
Ruhi A. Khan | Chief Business Officer | USD 573.9K | 50 | — | — |
Jennifer A. Doudna | Co-founder & Member of Scientific Advisory Board | — | 62 | — | — |
Ryan Fischesser | Interim Principal Accounting Officer & Controller | — | — | 118.85K | 0.12% |
Reigin Zawadzki | Chief People Officer | — | — | — | — |
Compensation is shown in the reported currency; data updated Oct 3, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Feb 24, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
5
$47,474.48
Net Transaction Value
−$47,474.48
Net selling
Most Active
Kelly Timothy P
2 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Feb 25, 26Feb 25, 2026 | Kelly Timothy P Direct | Sell | $12K$12,020.04 |
| Feb 24, 26Feb 24, 2026 | Albertson Tina M. Direct | Sell | $2.1K$2,089.36 |
| Feb 24, 26Feb 24, 2026 | Kelly Timothy P Direct | Sell | $6.2K$6,168.12 |
| Feb 24, 26Feb 24, 2026 | MCCLUNG BARBARA G Direct | Sell | $13.6K$13,598.48 |
| Feb 24, 26Feb 24, 2026 | Khan Ruhi Ahmad Direct | Sell | $13.6K$13,598.48 |
Summary
Insiders reported 0 buys worth $0.00 and 5 sells worth $47,474.48 over the last 12 months. That adds up to net selling of $47,474.48. Kelly Timothy P was the most active insider with 2 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -7.0% | +53.5% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at -7.0% over three years. Forward estimates point to Revenue at +53.5% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Caribou Biosciences, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about CRBU's management, answered from reported figures.
Who manages CRBU?
Caribou Biosciences, Inc. (CRBU) lists 9 active executives. The top listed executive is Barbara G. McClung, Chief Legal Officer & Corporate Secretary.
Are CRBU insiders buying or selling?
Recent insider activity shows net buying of $52.30M.
Continue the stock analysis
Jump to another research area for this company.